{"nctId":"NCT01701401","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV","startDateStruct":{"date":"2012-09"},"conditions":["Chronic Hepatitis C Virus"],"count":870,"armGroups":[{"label":"LDV/SOF 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18, with chronic genotype 1 HCV infection\n* HCV treatment-naive\n* HCV RNA \\> 10,000 IU/mL at screening\n* Cirrhosis determination; a liver biopsy may be required\n* Screening laboratory values within defined thresholds\n* Use of two effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Pregnant or nursing female or male with pregnant female partner\n* Co-infection with HIV or hepatitis B virus (HBV)\n* Current or prior history of clinical hepatic decompensation\n* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)\n* Chronic use of systemic immunosuppressive agents\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)","description":"SVR12 was defined as HCV RNA level \\< the lower limit of quantification (LLOQ, ie, \\< 25 copies/mL) 12 weeks after last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.2","spread":null},{"groupId":"OG002","value":"98.2","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug","description":"The percentage of participants who experienced an adverse event leading to permanent discontinuation from any study drug was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"1.8","spread":null},{"groupId":"OG003","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug","description":"SVR4 and SVR24 were defined as HCV RNA level \\< LLOQ at 4 and 24 weeks after discontinuation of study drug, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null},{"groupId":"OG002","value":"99.1","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.2","spread":null},{"groupId":"OG002","value":"98.2","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 2","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null},{"groupId":"OG001","value":"83.4","spread":null},{"groupId":"OG002","value":"82.9","spread":null},{"groupId":"OG003","value":"82.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 4","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 8","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99.5","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.90","spread":"0.657"},{"groupId":"OG001","value":"-4.94","spread":"0.633"},{"groupId":"OG002","value":"-4.86","spread":"0.670"},{"groupId":"OG003","value":"-4.89","spread":"0.648"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 4","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.99","spread":"0.697"},{"groupId":"OG001","value":"-5.02","spread":"0.623"},{"groupId":"OG002","value":"-4.93","spread":"0.678"},{"groupId":"OG003","value":"-4.96","spread":"0.651"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 8","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.99","spread":"0.696"},{"groupId":"OG001","value":"-5.02","spread":"0.625"},{"groupId":"OG002","value":"-4.91","spread":"0.702"},{"groupId":"OG003","value":"-4.96","spread":"0.651"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"On-treatment virologic failure was defined as:\n\n* Breakthrough: HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ, while on treatment, confirmed with 2 consecutive values (second confirmation value could have been posttreatment), or last available on-treatment measurement with no subsequent follow- up values, OR\n* Rebound: \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (second confirmation value could have been posttreatment), or last available on-treatment measurement with no subsequent follow-up values, OR\n* Nonresponse: HCV RNA persistently ≥ LLOQ through 8 weeks of treatment\n\nVirologic relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":214},"commonTop":["Fatigue","Headache","Insomnia","Nausea","Asthenia"]}}}